Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice.

[1]  I. Barr,et al.  Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA , 2011, Influenza and other respiratory viruses.

[2]  O. Kurskaya,et al.  Influenza A/H1N1pdm virus in Russian Asia in 2009-2010. , 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[3]  K. Broman,et al.  Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates , 2011, PLoS pathogens.

[4]  E. Andrews,et al.  A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. , 2011, Vaccine.

[5]  L. Yeolekar,et al.  A pandemic influenza vaccine in India: from strain to sale within 12 months. , 2011, Vaccine.

[6]  R. Bright,et al.  United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. , 2011, Vaccine.

[7]  H. van den Bosch,et al.  Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. , 2011, Vaccine.

[8]  Dayan Wang,et al.  Genomic Polymorphism of the Pandemic A (H1N1) Influenza Viruses Correlates with Viral Replication, Virulence, and Pathogenicity In Vitro and In Vivo , 2011, PloS one.

[9]  M. V. Van Kerkhove,et al.  Epidemiologic and virologic assessment of the 2009 influenza A (H1N1) pandemic on selected temperate countries in the Southern Hemisphere: Argentina, Australia, Chile, New Zealand and South Africa , 2011, Influenza and other respiratory viruses.

[10]  T. Tumpey,et al.  Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. , 2011, Vaccine.

[11]  Hang Xie,et al.  Immunogenicity and Cross-Reactivity of 2009–2010 Inactivated Seasonal Influenza Vaccine in US Adults and Elderly , 2011, PloS one.

[12]  C. N. Duarte Dos Santos,et al.  Laboratory Diagnosis, Epidemiology, and Clinical Outcomes of Pandemic Influenza A and Community Respiratory Viral Infections in Southern Brazil , 2011, Journal of Clinical Microbiology.

[13]  Xiufan Liu,et al.  Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. , 2011, Vaccine.

[14]  Ji-Ming Chen,et al.  Emergency surveillance of influenza during 2009 in the Chinese city of Qingdao , 2010, Influenza and other respiratory viruses.

[15]  M. Kieny,et al.  The 2009 A (H1N1) influenza virus pandemic: A review. , 2010, Vaccine.

[16]  Hualan Chen,et al.  Continued Evolution of H5N1 Influenza Viruses in Wild Birds, Domestic Poultry, and Humans in China from 2004 to 2009 , 2010, Journal of Virology.

[17]  Jeremy C. Jones,et al.  Influenza vaccines: the good, the bad, and the eggs. , 2010, Advances in virus research.

[18]  Lyn Finelli,et al.  Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. , 2009, The New England journal of medicine.

[19]  R. Compans,et al.  Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. , 2009, Antiviral research.

[20]  Z. Vajo,et al.  A Single-Dose Influenza A (H5N1) Vaccine Safe and Immunogenic in Adult and Elderly Patients: an Approach to Pandemic Vaccine Development , 2009, Journal of Virology.

[21]  F. Hayden,et al.  Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. , 2009, Vaccine.

[22]  Y. Kawaoka,et al.  Immunogenicity and Protective Efficacy of a Live Attenuated H5N1 Vaccine in Nonhuman Primates , 2009, PLoS pathogens.

[23]  R. Greenlee,et al.  Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. , 2009, The Journal of infectious diseases.

[24]  Robert Schechter,et al.  Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[25]  Weizhong Yang,et al.  Human Influenza A (H5N1) Cases, Urban Areas of People’s Republic of China, 2005–2006 , 2007, Emerging infectious diseases.

[26]  D. Fleming,et al.  Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine-Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care , 2006, Pediatrics.

[27]  B. Murphy,et al.  Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets , 2006, PLoS medicine.

[28]  B. Pulendran,et al.  Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. , 2006, Virology.

[29]  Hongjie Yu,et al.  Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China. , 2006, The New England journal of medicine.

[30]  D. Fedson.  Preparing for Pandemic Vaccination: An International Policy Agenda for Vaccine Development , 2005, Journal of public health policy.

[31]  R. Belshe.  Current status of live attenuated influenza virus vaccine in the US. , 2004, Virus research.

[32]  R. Cox,et al.  Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.

[33]  David Swayne,et al.  Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. , 2003, Vaccine.

[34]  Qi Chen,et al.  Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. , 2003, Vaccine.

[35]  G. Schuler,et al.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. , 1999, Journal of immunological methods.

[36]  Hans-Georg Rammensee,et al.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells , 1990, Nature.

[37]  F. Ennis,et al.  HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. , 1988, Journal of immunology.

[38]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.